Abstract
Aims:
To describe the clinical outcome of three patients with Behçet's disease maintained on infliximab who were switched to adalimumab therapy.
Methods:
Case note review. Main outcome measure was recurrence of uveitis.
Results:
All patients remained free of recurrence with stable visual acuities.
Conclusions:
Adalimumab appears to maintain disease remission in Behçet's disease.
MeSH terms
-
Adalimumab
-
Adult
-
Anti-Inflammatory Agents / therapeutic use*
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Behcet Syndrome / drug therapy*
-
Female
-
Humans
-
Male
-
Recurrence
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Uveitis / drug therapy*
Substances
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Tumor Necrosis Factor-alpha
-
Adalimumab